Peptide and compounding law · Updated
"Research use only" peptides: what the label does and does not do
A "research use only" or "not for human consumption" label does not decide whether a peptide is legal. The FDA judges intended use by everything the seller does, under 21 CFR 201.128: its website, its claims, what it sells alongside the vials, and who it knows is buying. When that evidence shows the peptide is meant for people, the FDA treats it as an unapproved new drug, and shipping it across state lines is a prohibited act under 21 U.S.C. 331(d). The FDA has sent at least a dozen such warning letters since 2024, and sellers have gone to federal prison.
| What the seller did | What the FDA concluded | Example |
|---|---|---|
| Sold bacteriostatic water with the peptides | The water is itself a drug, because the sale shows it is meant for injecting the peptides | Letter of August 24, 2026 (Cornelius, NC seller) |
| Offered a "peptide calculator" or dosing guide | These "collectively provide the means to prepare an injectable drug for human administration" | Letter of August 24, 2026 |
| Linked to studies on weight loss or other benefits in people | Evidence of intended human use, even when the claims are someone else's | Letter of August 24, 2026 (Cornelius, NC seller) |
| Used code names such as "GLP-2 Tirz" or "GLP-3 RT" for approved or investigational drugs | The products are tirzepatide and retatrutide by another name | Letters of March 31, 2026 |
| Sold peptides that are the active ingredients of approved drugs (PT-141, tesamorelin) | Unapproved new drugs when sold outside the approved product | Letter of August 24, 2026 |
| Labeled every product "research use only" and "not for human consumption" | "Despite statements on your product labeling ... evidence obtained from your website establishes that your products are intended to be drugs for human use" | The same sentence appears in every letter in this table |
Where "research use only" comes from, and why it does not apply
The phrase has a real home in federal law, but not for drugs. 21 CFR 809.10(c) lets an in vitro diagnostic product still in laboratory development ship without full labeling if it carries the statement "For Research Use Only. Not for use in diagnostic procedures." In vitro diagnostics are reagents and instruments used to examine specimens taken from the body, and the rule treats them as devices (21 CFR 809.3).
A peptide that someone will inject or swallow is not a diagnostic reagent. If it is meant to treat a condition or to affect the body, it is a drug (21 U.S.C. 321(g)(1)), and there is no research-use exemption that lets a seller market an unapproved drug to the public.
How the FDA decides what a product is for
Under 21 CFR 201.128, intended use is "the objective intent of the persons legally responsible for the labeling". It can be shown by "labeling claims, advertising matter, or oral or written statements", and also by "circumstances in which the article is, with the knowledge of such persons or their representatives, offered or used for a purpose for which it is neither labeled nor advertised". The current text dates from the FDA's intended-use rule of August 2, 2021 (86 FR 41401).
In practice the label loses to the website. Dosing charts, reconstitution instructions, "before and after" content, customer reviews about results, and syringes or bacteriostatic water in the same cart all show what the seller expects buyers to do.
The warning letters, 2024 to 2026
The FDA's warning-letter database returns about twenty letters using the exact phrase "research use only". The peptide letters follow one pattern: the products are drugs, they are new drugs because they are not generally recognized as safe and effective, and shipping them without approval violates 21 U.S.C. 355(a) and 331(d).
The letters came in waves: December 2024 (four sellers of semaglutide, tirzepatide, retatrutide and similar drugs), March 31, 2026 (five more, most selling code-named GLP-1 products with bacteriostatic water), and August 24, 2026 (five sellers of GLP-1s, PT-141, tesamorelin and SS-31, one of them in North Carolina). The FDA's GLP-1 page says it has also warned ingredient distributors selling retatrutide and other GLP-1 drugs to compounders.
Criminal cases
Warning letters are not the end of it. On July 30, 2026 the owner of Paradigm Peptides, an Indiana seller of peptides, SARMs and hCG, was sentenced in federal court to five years and ten months (DOJ); investigators said the products were unapproved new drugs. A co-defendant was sentenced to one year and four months.
On July 23, 2026 a Michigan man was sentenced to 21 months in prison for conspiring to introduce misbranded drugs into the market with intent to defraud and mislead the FDA and consumers. The websites that sold them, semaglutide and tirzepatide among them, said the drugs were "for research purposes only", although, prosecutors said, the sellers knew customers would use them personally (DOJ, W.D. Mich.).
Licensed professionals are not outside this. A Kentucky compounding pharmacy and its owner pleaded guilty in October 2020 to distributing unapproved new drugs, with BPC-157 and other peptides among the drugs named in the plea agreement (DOJ, E.D. Ky.). In April 2026 a federal grand jury in Utah indicted a physician who allegedly obtained peptides from China that he knew were not FDA-approved and sold them to his patients (DOJ, D. Utah); an indictment is an allegation, not a finding of guilt.
Under 21 U.S.C. 333(a), a prohibited act is a misdemeanor punishable by up to a year in prison, and a felony punishable by up to three years when it is done with intent to defraud or mislead.
The HHS policy is not a way in for research sellers
On October 30, 2026, HHS said it does not intend to take enforcement action against "a State-licensed pharmacy, Federal facility, or licensed physician" compounding with six peptides listed in the appendix of a draft policy: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 (91 FR 68526; HHS policy). Its conditions include a label reading "This is a compounded drug product. Not for resale." The policy is about compounding under section 503A, which means a pharmacy or physician making a drug for an identified patient on a prescription. It does not cover peptides sold as research chemicals. If anything it sharpens the line: there is now a compounding channel for the peptides it lists, and a research label is not it. See Are peptides legal?
North Carolina
Federal cases against peptide sellers are not new in Charlotte. In 2014 two Charlotte men pleaded guilty in federal court to selling misbranded drugs, including "peptides", through two companies they ran from 2010 to January 2014, mainly to bodybuilders (DOJ, W.D.N.C.).
The FDA's August 24, 2026 letters included one to a research-peptide seller in Cornelius, in Mecklenburg County, which sold tirzepatide, semaglutide, retatrutide, PT-141 and tesamorelin with bacteriostatic water (FDA). A business selling from North Carolina answers to the FDA and to the state's own drug and controlled-substance laws.
The lawful channel in North Carolina runs through licensed pharmacies. The Board of Pharmacy's rule lets a pharmacy dispense a compounded drug only on a valid prescription and says compounded preparations "shall not be offered to other entities for resale" (21 NCAC 46 .2801).
If you sell, or are thinking of selling, research peptides
- Assume the FDA will read the whole site, the product names, the add-ons and the reviews, not the label.
- A warning letter gives 15 working days to respond in writing. Answer it with counsel, and treat it as the start of a file, not a formality.
- A lawful route exists for some products: an FDA-approved drug, a compounding pharmacy within section 503A or 503B, or a properly regulated clinical trial.
Common questions
Is it legal to sell peptides labeled "research use only"?
Selling to genuine laboratories for research is one thing. Selling to the public when the website, products or add-ons show the peptides are meant for people is, in the FDA's view, selling unapproved new drugs, whatever the label says.
Does "not for human consumption" protect the seller?
No. Every recent FDA letter to a peptide seller quotes that wording and then explains why the rest of the website shows the products are intended for human use.
Is buying research peptides illegal?
Federal drug law is aimed mainly at the people who sell and ship unapproved drugs. A buyer gets no assurance of identity, purity or dose, and state controlled-substance laws are a separate matter.
Does the October 30, 2026 HHS policy cover research peptides?
No. It covers 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians, for six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), under its conditions. Research chemicals are outside it.
What does the FDA look at besides the label?
Website claims and links, dosing charts and calculators, bacteriostatic water and syringes sold with the vials, code names for approved drugs, customer reviews, and what the seller knows about its buyers.
What happens after an FDA warning letter?
The FDA asks for a written response within 15 working days explaining the corrections, and the letters warn that failing to correct the violations may lead to legal action without further notice, including seizure and injunction.
Update log
- November 2, 2026. Published. Federal regulations and FDA warning letters checked October 30, 2026; the HHS notice and docket re-checked November 2, 2026; the HHS policy's Appendix A and four Justice Department releases read at the source the same day.
Sources
- 21 CFR 201.128 (intended use)
- 21 CFR 809.10 and 809.3 (in vitro diagnostic labeling; research use only)
- 21 U.S.C. 321 (definition of drug)
- 21 U.S.C. 331 (prohibited acts)
- 21 U.S.C. 355 (new drugs)
- FDA warning letter, August 24, 2026 (Cornelius, NC peptide seller)
- FDA warning letter, August 24, 2026 (peptide seller, Phoenix, AZ)
- U.S. Department of Justice, United States v. Matthew Kawa (N.D. Ind.)
- U.S. Attorney's Office, W.D. Mich., sentencing release (July 23, 2026)
- U.S. Attorney's Office, E.D. Ky., Nicholasville compounding pharmacy and its owner sentenced (February 24, 2021)
- U.S. Attorney's Office, D. Utah, physician indicted over misbranded drugs from China (April 1, 2026)
- U.S. Attorney's Office, W.D.N.C., two Charlotte men plead guilty to selling misbranded drugs (November 13, 2014)
- HHS peptide enforcement discretion policy, 91 FR 68526 (Oct. 30, 2026)
- HHS, the policy with Appendix A (peptides covered), hhs.gov PDF (read November 2, 2026)
- 21 U.S.C. 333 (penalties)
- 21 NCAC 46 .2801 (North Carolina compounding rule; Cornell LII copy)
Related
Received an FDA letter, or reviewing a peptide business?
DPS Law advises peptide businesses, clinics and pharmacies on North Carolina and federal drug law. For another state's rules, talk to a lawyer licensed in that state.